160 related articles for article (PubMed ID: 38573021)
1. Ursodeoxycholic acid may protect from severe acute respiratory syndrome coronavirus 2 Omicron variant by reducing angiotensin-converting enzyme 2.
Lee K; Na Y; Kim M; Lee D; Choi J; Kim G; Kim MS
Pharmacol Res Perspect; 2024 Apr; 12(2):e1194. PubMed ID: 38573021
[TBL] [Abstract][Full Text] [Related]
2. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2.
Brevini T; Maes M; Webb GJ; John BV; Fuchs CD; Buescher G; Wang L; Griffiths C; Brown ML; Scott WE; Pereyra-Gerber P; Gelson WTH; Brown S; Dillon S; Muraro D; Sharp J; Neary M; Box H; Tatham L; Stewart J; Curley P; Pertinez H; Forrest S; Mlcochova P; Varankar SS; Darvish-Damavandi M; Mulcahy VL; Kuc RE; Williams TL; Heslop JA; Rossetti D; Tysoe OC; Galanakis V; Vila-Gonzalez M; Crozier TWM; Bargehr J; Sinha S; Upponi SS; Fear C; Swift L; Saeb-Parsy K; Davies SE; Wester A; Hagström H; Melum E; Clements D; Humphreys P; Herriott J; Kijak E; Cox H; Bramwell C; Valentijn A; Illingworth CJR; ; Dahman B; Bastaich DR; Ferreira RD; Marjot T; Barnes E; Moon AM; Barritt AS; Gupta RK; Baker S; Davenport AP; Corbett G; Gorgoulis VG; Buczacki SJA; Lee JH; Matheson NJ; Trauner M; Fisher AJ; Gibbs P; Butler AJ; Watson CJE; Mells GF; Dougan G; Owen A; Lohse AW; Vallier L; Sampaziotis F
Nature; 2023 Mar; 615(7950):134-142. PubMed ID: 36470304
[TBL] [Abstract][Full Text] [Related]
3. Protective effect of ursodeoxycholic acid on COVID-19 in patients with chronic liver disease.
Li Y; Zhu N; Cui X; Lin Y; Li X
Front Cell Infect Microbiol; 2023; 13():1178590. PubMed ID: 37207192
[TBL] [Abstract][Full Text] [Related]
4. Epistasis at the SARS-CoV-2 Receptor-Binding Domain Interface and the Propitiously Boring Implications for Vaccine Escape.
Rochman ND; Faure G; Wolf YI; Freddolino PL; Zhang F; Koonin EV
mBio; 2022 Apr; 13(2):e0013522. PubMed ID: 35289643
[TBL] [Abstract][Full Text] [Related]
5. Ursodeoxycholic acid administration did not reduce susceptibility to SARS-CoV-2 infection in children.
Liu T; Wang JS
Liver Int; 2023 Sep; 43(9):1950-1954. PubMed ID: 37381749
[TBL] [Abstract][Full Text] [Related]
6. Ursodeoxycholic acid ameliorates cell migration retarded by the SARS-CoV-2 spike protein in BEAS-2B human bronchial epithelial cells.
Thuy PX; Bao TDD; Moon EY
Biomed Pharmacother; 2022 Jun; 150():113021. PubMed ID: 35658221
[TBL] [Abstract][Full Text] [Related]
7. Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization.
Kim Y; Gaudreault NN; Meekins DA; Perera KD; Bold D; Trujillo JD; Morozov I; McDowell CD; Chang KO; Richt JA
Microbiol Spectr; 2022 Jun; 10(3):e0178921. PubMed ID: 35638818
[TBL] [Abstract][Full Text] [Related]
8. Ursodeoxycholic acid is associated with a reduction in SARS-CoV-2 infection and reduced severity of COVID-19 in patients with cirrhosis.
John BV; Bastaich D; Webb G; Brevini T; Moon A; Ferreira RD; Chin AM; Kaplan DE; Taddei TH; Serper M; Mahmud N; Deng Y; Chao HH; Sampaziotis F; Dahman B
J Intern Med; 2023 May; 293(5):636-647. PubMed ID: 37018129
[TBL] [Abstract][Full Text] [Related]
9. Molecular and computational analysis of spike protein of newly emerged omicron variant in comparison to the delta variant of SARS-CoV-2 in Iraq.
Rashid PMA; Salih GF
Mol Biol Rep; 2022 Aug; 49(8):7437-7445. PubMed ID: 35698014
[TBL] [Abstract][Full Text] [Related]
10. Oxalic acid blocked the binding of spike protein from SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variants to human angiotensin-converting enzymes 2.
Wang M; Yan H; Chen L; Wang Y; Li L; Zhang H; Miao L
PLoS One; 2023; 18(5):e0285722. PubMed ID: 37200310
[TBL] [Abstract][Full Text] [Related]
11. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
[TBL] [Abstract][Full Text] [Related]
12. High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses.
Sims JJ; Lian S; Meggersee RL; Kasimsetty A; Wilson JM
PLoS One; 2022; 17(8):e0271359. PubMed ID: 36006993
[TBL] [Abstract][Full Text] [Related]
13. Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation.
Rodriguez JA; Gonzalez J; Arboleda-Bustos CE; Mendoza N; Martinez C; Pinzon A
Chem Biol Interact; 2022 Dec; 368():110244. PubMed ID: 36336003
[TBL] [Abstract][Full Text] [Related]
14. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
[TBL] [Abstract][Full Text] [Related]
15. A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model.
Ma J; Liu X; Zhou M; Chen P; Chen R; Wang J; Zhu H; Wu K; Ye J; Zhang Y; Yuan Q; Tang Q; Yuan L; Cheng T; Guan Y; Xia N
J Virol; 2023 Feb; 97(2):e0168422. PubMed ID: 36651747
[TBL] [Abstract][Full Text] [Related]
16. Structural basis of increased binding affinities of spikes from SARS-CoV-2 Omicron variants to rabbit and hare ACE2s reveals the expanding host tendency.
Shi K; Li L; Luo C; Xu Z; Huang B; Ma S; Liu K; Yu G; Gao GF
mBio; 2024 Feb; 15(2):e0298823. PubMed ID: 38112468
[TBL] [Abstract][Full Text] [Related]
17. Structural Basis for Human Receptor Recognition by SARS-CoV-2 Omicron Variant BA.1.
Geng Q; Shi K; Ye G; Zhang W; Aihara H; Li F
J Virol; 2022 Apr; 96(8):e0024922. PubMed ID: 35343765
[TBL] [Abstract][Full Text] [Related]
18. Mucosal immunization with Ad5-based vaccines protects Syrian hamsters from challenge with omicron and delta variants of SARS-CoV-2.
Braun MR; Martinez CI; Dora EG; Showalter LJ; Mercedes AR; Tucker SN
Front Immunol; 2023; 14():1086035. PubMed ID: 36911687
[TBL] [Abstract][Full Text] [Related]
19. Effect of ursodeoxycholic acid on preventing SARS-CoV-2 infection in patients with liver transplantation: a multicenter retrospective cohort study.
Hu L; Zhang H; Huang C; Shen T; Feng Z; Mu F; Xu L; Lin Y; Yue C; Guo K; Tian M; Shi J; Zhang C; Wen P; Cao S; Wang Y; Zhang J; Shi X; Wang Z; He Y; Zhang X; Liu X; Lv Y; Liu Z; Guo W; Wang B
QJM; 2024 Jun; 117(5):339-347. PubMed ID: 37950449
[TBL] [Abstract][Full Text] [Related]
20. Soluble Angiotensin-Converting Enzyme 2 Protein Improves Survival and Lowers Viral Titers in Lethal Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Type 2 Infection with the Delta Variant.
Cianfarini C; Hassler L; Wysocki J; Hassan A; Nicolaescu V; Elli D; Gula H; Ibrahim AM; Randall G; Henkin J; Batlle D
Cells; 2024 Jan; 13(3):. PubMed ID: 38334597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
